Skip to NavigationSkip to content

Summary of Wegener’s Granulomatosis - ref #BS000010

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Wegener’s Granulomatosis

in 9 Major Markets Wegener’s Granulomatosis (WG), also known as granulomatous with polyangiitis, is an autoimmune disease, involving necrotizing vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). WG primarily involves the upper and lower respiratory tracts and kidneys and originates from an inherited genetic component coupled with an unknown environment stimulus. This report provides the current prevalent population for WG across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of WG have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for WG include:

  • Renal complications
  • Other autoimmune conditions
  • Respiratory complications
  • Neurological complications
  • Various vascular manifestations
  • Deafness

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global WG’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of WG and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on WG’s prevalent population.
  • Identify sub-populations within WG which require treatment.
  • Gain an understanding of the specific markets that have the largest number of WG patients.

The content of this report includes:

  • List of Tables & Figures
  • Overview
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis &Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Wegener’s Granulomatosis
  • Main Complications and Presenting Features of Wegener’s Granulomatosis
    • Vascular Manifestations
    • ANCA Serology Status
    • Respiratory Complications of Wegner’s Granulomatosis
    • ENT Features of Wegner’s Granulomatosis 
    • Neurological Features of Wegner’s Granulomatosis
    • Renal Involvement of Wegner’s Granulomatosis
  • References
  • Appendix

Tables and figures within this report include:

  • Prevalence of WG, total (000s)
  • Prevalence of WG, males (000s)
  • Prevalence of WG, females (000s)
  • WG by vascular manifestation, total (000s)
  • ANCA serology status at presentation for WG, total (000s)
  • Respiratory infiltrates & effusions in patients with WG, total (000s)
  • Presence of lung inflammation in patients with WG, total (000s)
  • ENT features at presentation of patients with WG, total (000s)
  • Neurological involvement at presentation of patients with WG, total (000s)
  • Presence of abnormal glomeruli in patients with WG, total (000s)
  • USA Prevalence of WG by 5-yr age cohort, males (000s)
  • USA Prevalence of WG by 5-yr age cohort, females (000s)
  • France Prevalence of WG by 5-yr age cohort, males (000s)
  • France Prevalence of WG by 5-yr age cohort, females (000s)
  • Germany Prevalence of WG by 5-yr age cohort, males (000s)
  • Germany Prevalence of WG by 5-yr age cohort, females (000s)
  • Italy Prevalence of WG by 5-yr age cohort, males (000s)
  • Italy Prevalence of WG by 5-yr age cohort, females (000s)
  • Spain Prevalence of WG by 5-yr age cohort, males (000s)
  • Spain Prevalence of WG by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of WG by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of WG by 5-yr age cohort, females (000s)
  • Brazil Prevalence of WG by 5-yr age cohort, males (000s)
  • Brazil Prevalence of WG by 5-yr age cohort, females (000s)
  • Japan Prevalence of WG by 5-yr age cohort, males (000s)
  • Japan Prevalence of WG by 5-yr age cohort, females (000s)
  • India Prevalence of WG by 5-yr age cohort, males (000s)
  • India Prevalence of WG by 5-yr age cohort, females (000s)

Publisher: Black Swan
Date published: August 2015

Price: £ 3,950.00

You need to agree to the Terms and Conditions before placing your order

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches